654 Real world incidence of grade III and higher adverse effects, emergency room utilization and hospital admissions during treatment with commonly used PD-1/PDL-1 targeting immune check point inhibitors

• Nerea Lopetegui Lia,
• Syed Imran Jafri,
• Khalid Shalaby,
• Dimitrios Drekolias,
• James Vredenburgh

Affiliations

Nerea Lopetegui Lia

1University of Connecticut, Hartford, CT, USA

Syed Imran Jafri

2University of Connecticut Health Center, Farmington, CT, USA

Khalid Shalaby

1University of Connecticut, Hartford, CT, USA

Dimitrios Drekolias

1University of Connecticut, Hartford, CT, USA

James Vredenburgh

3Smilow Cancer Hospital at St Francis Hos, Hartford, CT, USA